Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma

2015314 citationsJournal Articlegreen Open Access

Authors

Brian M. Slomovitz

Yunyun Jiang

Abstract

Everolimus plus letrozole results in a high CBR and RR in patients with recurrent EC. Further development of this combination in recurrent endometrioid EC is under way.

Topics & Keywords

PI3K/AKT/mTOR signaling in cancer Cancer Mechanisms and Therapy Advanced Breast Cancer Therapies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 33, Issue 8, pp. 930-936

DOI: 10.1200/jco.2014.58.3401

Field-Weighted Citation Impact: 12.95